Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
2.320
-0.150 (-6.07%)
At close: Feb 21, 2025, 4:00 PM
2.280
-0.040 (-1.72%)
After-hours: Feb 21, 2025, 7:32 PM EST
Zentalis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Zentalis Pharmaceuticals stock have an average target of 8.53, with a low estimate of 2.20 and a high estimate of 20. The average target predicts an increase of 267.67% from the current stock price of 2.32.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Zentalis Pharmaceuticals stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 4 | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 7 | 8 | 8 | 8 | 8 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Wells Fargo | Wells Fargo | Hold Maintains $8 → $6 | Hold | Maintains | $8 → $6 | +158.62% | Jan 30, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $10 | Strong Buy | Maintains | $20 → $10 | +331.03% | Jan 29, 2025 |
UBS | UBS | Hold Maintains $5 → $2.2 | Hold | Maintains | $5 → $2.2 | -5.17% | Jan 28, 2025 |
Guggenheim | Guggenheim | Strong Buy Maintains $12 → $8 | Strong Buy | Maintains | $12 → $8 | +244.83% | Nov 15, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +762.07% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
37.34M
Revenue Next Year
n/a
from 37.34M
EPS This Year
-2.45
from -4.47
EPS Next Year
-2.61
from -2.45
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 43.1M | n/a | 177.6M | |||
Avg | 37.3M | n/a | 20.9M | |||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -2.36 | -1.73 | -1.71 | |||
Avg | -2.45 | -2.61 | -2.54 | |||
Low | -2.61 | -3.25 | -3.53 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.